Russell Investments Group Ltd. Purchases 433,855 Shares of Organon & Co. (NYSE:OGN)

Russell Investments Group Ltd. boosted its holdings in Organon & Co. (NYSE:OGN - Free Report) by 47.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,356,332 shares of the company's stock after buying an additional 433,855 shares during the quarter. Russell Investments Group Ltd. owned 0.53% of Organon & Co. worth $19,558,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. AE Wealth Management LLC acquired a new stake in shares of Organon & Co. during the third quarter valued at approximately $305,000. Exchange Traded Concepts LLC acquired a new stake in shares of Organon & Co. in the third quarter worth $165,000. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Organon & Co. by 8.2% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 24,159 shares of the company's stock valued at $419,000 after buying an additional 1,838 shares in the last quarter. Xponance Inc. raised its position in Organon & Co. by 4.4% during the third quarter. Xponance Inc. now owns 42,535 shares of the company's stock valued at $738,000 after buying an additional 1,798 shares during the period. Finally, Raymond James & Associates lifted its stake in Organon & Co. by 0.7% in the 3rd quarter. Raymond James & Associates now owns 345,810 shares of the company's stock worth $6,003,000 after acquiring an additional 2,354 shares in the last quarter. Institutional investors own 77.43% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on OGN shares. The Goldman Sachs Group upped their target price on Organon & Co. from $18.00 to $20.00 and gave the company a "neutral" rating in a report on Friday. Piper Sandler lifted their target price on shares of Organon & Co. from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Monday.

Insider Transactions at Organon & Co.

In other Organon & Co. news, insider Kirke Weaver purchased 2,720 shares of the business's stock in a transaction dated Thursday, February 22nd. The stock was bought at an average cost of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the acquisition, the insider now directly owns 15,181 shares in the company, valued at $278,723.16. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.17% of the stock is currently owned by corporate insiders.

Organon & Co. Stock Up 0.6 %

OGN stock traded up $0.11 during trading hours on Friday, hitting $19.61. The company's stock had a trading volume of 3,217,321 shares, compared to its average volume of 2,725,945. The stock has a 50 day moving average price of $18.17 and a two-hundred day moving average price of $15.75. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $24.08. The company has a market capitalization of $5.04 billion, a PE ratio of 4.88, a price-to-earnings-growth ratio of 0.89 and a beta of 0.81.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.73 by $0.14. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. The firm had revenue of $1.60 billion during the quarter, compared to analysts' expectations of $1.55 billion. Sell-side analysts expect that Organon & Co. will post 4.1 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Monday, May 13th will be given a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 5.71%. The ex-dividend date is Friday, May 10th. Organon & Co.'s dividend payout ratio is currently 28.00%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.